Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo lower volume Clear all
Terminated Phase 3 Interventional Results available

Tranexamic Acid Use to Reduce Blood Transfusion in Pediatric Cancer Patients Undergoing Limb Salvage Procedure

NCT04410042
View directory record Official record
Conditions
Cancer of the Bone, Limb Salvage
Interventions
Tranexamic Acid, 0.9% sodium chloride
Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

NCT01030575
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions
Inositol lower volume, Inositol mid-level volume, Inositol high volume, Placebo low volume
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
12 Hours to 72 Hours
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 22, 2026, 2:38 PM EDT
Withdrawn Phase 4 Interventional

Evolocumab In Advanced Chronic Kidney Disease Trial

NCT04510844
View directory record Official record
Conditions
Chronic Kidney Diseases, High Cholesterol
Interventions
Evolocumab, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Mineola, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 22, 2026, 2:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pedal Pump and Leg Lymphedema

NCT06235463
View directory record Official record
Conditions
Lymphedema
Interventions
Osteopathic Pedal Pump, Light Touch Treatment
Other
Lead sponsor
Rowan University
Other
Eligibility
55 Years to 100 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Stratford, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 22, 2026, 2:38 PM EDT
Recruiting Phase 1 Interventional

Adia Med of Winter Park LLC Lower Back Pain Research Study

NCT07587047
View directory record Official record
Conditions
Chronic Mechanical Lower Back Pain, Lower Back Pain, Chronic Lower Back Pain
Interventions
Umbilical Cord Blood-Derived Stem Cells and Exosomes, Placebo IV
Biological · Other
Lead sponsor
Adia Med of Winter Park LLC
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Winter Park, Florida
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 22, 2026, 2:38 PM EDT
Not listed Phase 4 Interventional

Denosumab Administration After Spinal Cord Injury

NCT01983475
View directory record Official record
Conditions
Osteoporosis, Spinal Cord Injury
Interventions
Denosumab, Placebo (identical Denosumab volume of normal saline)
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

NCT01464307
View directory record Official record
Conditions
Post-stroke Spasticity of the Lower Limb
Interventions
IncobotulinumtoxinA (400 Units), Placebo Comparator
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
12
States / cities
Downey, California • Long Beach, California • Fairfield, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion

NCT01222117
View directory record Official record
Conditions
Acute Peripheral Arterial Occlusion
Interventions
Plasmin, Plasminogen Activator, Placebo
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Not applicable Interventional

Augmenting a Post-Stroke Wellness Program With Respiratory Muscle Training

NCT05819333
View directory record Official record
Conditions
Stroke
Interventions
Exercise Program + Respiratory Strength Training, Exercise Program + Respiratory Relaxation Training
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 95 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse

NCT03539887
View directory record Official record
Conditions
Suicidal Ideation, Depression, Alcohol Abuse
Interventions
Intranasal ketamine, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 22, 2026, 2:38 PM EDT
Recruiting Phase 3 Interventional

Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression

NCT06112990
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
creatine monohydrate, Placebo, Home-based, telehealth
Dietary Supplement · Other · Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

Nurse Managed Upper Body Strength Training in Chronic Obstructive Pulmonary Disease (COPD)

NCT01057797
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Exercise-specific self-efficacy, Gentle chair exercise, upper body strength training
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
45 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 27, 2010 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon

NCT05935527
View directory record Official record
Conditions
Lower Eyelid Steatoblepharon
Interventions
POLAT-001, Placebo
Drug
Lead sponsor
Peregrine Ophthalmic
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Newport Beach, California • Coral Gables, Florida • Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

NCT04589403
View directory record Official record
Conditions
Healthy
Interventions
OPT101
Drug
Lead sponsor
Op-T LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 22, 2026, 2:38 PM EDT
Recruiting Phase 4 Interventional

Dysport ® as an Adjunctive Treatment to Bracing in the Management of Adolescent Idiopathic Scoliosis

NCT03935295
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
AbobotulinumtoxinA, Placebos, Custom Thoracolumbosacral Orthosis
Drug · Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
10 Years to 16 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 22, 2026, 2:38 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect

NCT01589081
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Intravenous Nicotine, Progesterone
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 22, 2026, 2:38 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

IV Nicotine Induced Changes in Hormone Function, Mood States and Behavior

NCT01589055
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Intravenous Nicotine
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

NCT01144338
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide Once Weekly, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
14,752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
139
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Rivastigmine Study in Adolescents With Down Syndrome

NCT01084135
View directory record Official record
Conditions
Down Syndrome
Interventions
Rivastigmine, Liquid Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
10 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 22, 2026, 2:38 PM EDT
Not listed Not applicable Interventional

Negative Work Exercise for the Treatment of Knee Arthritis

NCT02098096
View directory record Official record
Conditions
Osteoarthritis, Arthritis
Interventions
Negative Work, Stretching
Other
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
50 Years to 70 Years · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 22, 2026, 2:38 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity

NCT04099667
View directory record Official record
Conditions
Spasticity
Interventions
Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo
Drug
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Beverage Volume, Glycerol Concentration, and Sodium Concentration on Fluid Balance in Healthy Euhydrated Men and Women at Rest

NCT06854471
View directory record Official record
Conditions
Fluid Balance
Interventions
Placebo beverage, kiwi-strawberry flavor, Electrolyte solution without glycerol beverage 1, Electrolyte solution without glycerol beverage 2, Electrolyte solution without glycerol beverage 3, Electrolyte solution with glycerol beverage 1, Electrolyte solution with glycerol beverage 2, Electrolyte solution with glycerol beverage 3, Base with glycerol, no electrolytes beverage 1, Base with glycerol, no electrolytes beverage 2, Base with glycerol, no electrolytes beverage 3
Other
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Bradenton, Florida • St. Petersburg, Florida • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

Dysport® Pediatric Lower Limb Spasticity Study

NCT01249417
View directory record Official record
Conditions
Cerebral Palsy, Muscle Spasticity, Children
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
2 Years to 17 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Aurora, Colorado • Chicago, Illinois • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 22, 2026, 2:38 PM EDT
Terminated Phase 3 Interventional Results available

Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia

NCT01227512
View directory record Official record
Conditions
Hyponatremia, Dilutional Hyponatremia, Inappropriate ADH Syndrome
Interventions
tolvaptan, Fluid Restriction
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
56
States / cities
Birmingham, Alabama • Mobile, Alabama • Azusa, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 22, 2026, 2:38 PM EDT